Business Wire

NY-ALVAREZ-&-MARSAL

18.1.2023 07:01:35 CET | Business Wire | Press release

Share
Alvarez & Marsal Announces 2023 Managing Director Promotions

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.

Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”

Asia

Henry Chambers, Hong Kong

Eden Chen, Shanghai

Sally Sun, Hong Kong

Brazil

Pedro Bortolotto, São Paulo

Marcelo Compte, São Paulo

Rodrigo Domingues, São Paulo

Lilian Giorgi, São Paulo

Rodrigo Hong, São Paulo

Henrique Kanashiro, São Paulo

Rafael Mendonca Rodrigues, São Paulo

Fabio Missiato, São Paulo

Corporate Performance Improvement

Tiffany Guthrie, Houston

Mike Hall, San Francisco

John McKinnis, Dallas

Sam Rudkin, Atlanta

Consumer and Retail Group

Kenneth Cochran, Charlotte

Jeffrey Dwyer, Chicago

Lakshman Lakshmanan, Dallas

Chad Lusk, Chicago

Joanna Rangarajan, New York

Global Disputes and Investigations

Lee Betteridge, London

Gary Foster, London

EMEA – Performance Improvement

Private Equity Performance Improvement

Nicola Barbini, London

Chris Gobby, London

Britta Mittler, Frankfurt

Till Prinz, Dusseldorf

Tim Veen, Munich

Gerardo Villalba Bello, Madrid

Ysabel Gaspar Zayco, London

Financial Services Industry

Robert Bradbury, London

Dominic Roope, London

Corporate Transformation

Jatin Arora, Dubai

Mark Bennett, Paris

Daran Hopper, London

Dirk Naujokat, Munich

Steve Trainor, London

Diana Wong, London

EMEA Restructuring

Insolvency

Barry Lynch, Grand Cayman

Helen Skeates, London

Turnaround

David Johnston, London

José Miguel Gómez Rivas, Madrid

Middle East

Bill Ozturk, Dubai

Environmental, Social and Governance (ESG)

Stephanie Weiler, Chicago

Healthcare Industry Group

JoyAnn Book, Phoenix

Bianca A. Briola Charlotte

David Nidetz, Detroit

Rich Rieger, Chicago

India

Anup Gandhi, Mumbai

Pranav Sheth, Mumbai

Infrastructure & Capital Projects

Sue Frost, Washington, D.C.

Alan Richard, Washington, D.C.

Private Equity Performance Group

Kent Edgerton, Nashville

Jana Gold, Washington, D.C.

Brad Howard, New York

Larry Thomas, Tampa

Klaus Weisenberger, San Francisco

Public Sector

Daniel Harlan, Washington, D.C

Restructuring & Turnaround (North America)

Taylor Atwood, Dallas

Matthew Davidson, Detroit

Chad Ellison, Calgary

Kamila Khairoullina, New York

Mark Sidorenkov, Phoenix

Jeff Sielinski, Detroit

Michael Zembillas, Atlanta

Global Taxand

Simon Bernstein, New York

Stephanie Doughty, Houston

Michael Farkas, New York

Simon Gore, London

Jack Hollyman, London

Jac Emilio Martinez, Miami

Joseph Plati, New York

Brendan Sinnott, New York

Katya Umanskaya, Los Angeles

Global Transaction Advisory Group

Anuj Astir, New York

Nout Brugman, Amsterdam

David Cho, Chicago

Vitor Garcia, Sao Paulo

Jimmy Glenn, Atlanta

Nick Lynch, London

Jai Tandan, Mumbai

Rhett Taylor, Nashville

Nick Thoele, New York

Cedric Zana, Paris

Valuation Services

Cole Corbin, New York

Steven Fischoff, Chicago

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.

With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.

To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release

Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye